Bolt Biotherapeutics, Inc. (BOLT) — Institutional Holders, Q2 2026
23 institutional investment managers reported a BOLT position on SEC Form 13F-HR for the quarter ended June 30, 2026, with a combined reported value of $2.3M. Every filer is listed below, ranked by position value. Put and call option positions are excluded, and a firm filing several lots or share classes is shown once with its total.
BOLT in Q2 2026: what funds did
Funds that filed a 13F for both Q1 2026 and Q2 2026, by what they did with the common stock. Share counts are adjusted for any split between the two quarters; dollar figures are the change in shares at this quarter’s price.
Biggest buyers
- CITADEL ADVISORSAdded · +46,794 sh+$180.2K
- RENAISSANCE TECHNOLOGIESAdded · +21,400 sh+$82.4K
- NewEdge AdvisorsNew · +2,530 sh+$9.7K
- Tower Research Capital (TRC)Added · +617 sh+$2.4K
- Shay CapitalAdded · +533 sh+$2.1K
Biggest sellers
- Pivotal bioVenture Partners Investment AdvisorSold out · -42,581 sh-$163.9K
- Nan Fung Group LtdTrimmed · -24,250 sh-$93.4K
- SUSQUEHANNA INTERNATIONAL GROUP, LLPSold out · -11,657 sh-$44.9K
- GEODE CAPITAL MANAGEMENTTrimmed · -9,672 sh-$37.2K
- UBS Group AGTrimmed · -532 sh-$2.0K
BOLT 13F holders ranked 1–23 of 23
| # | Institution | Shares | Value | % of portfolio | QoQShares vs Q1 2026 |
|---|---|---|---|---|---|
| 1 | Sofinnova Ventures#1 · 137,721 sh | 137,721 | $530.2K | 0.03% | 0.0% |
| 2 | RENAISSANCE TECHNOLOGIES#2 · 98,625 sh | 98,625 | $379.7K | <0.01% | +27.7% |
| 3 | Vivo Capital#3 · 72,414 sh | 72,414 | $278.8K | 0.03% | 0.0% |
| 4 | CITADEL ADVISORS#4 · 56,903 sh | 56,903 | $219.1K | 0.00% | +462.9% |
| 5 | T3 Companies#5 · 38,000 sh | 38,000 | $146.3K | — | 0.0% |
| 6 | Board of Trustees of The Leland Stanford Junior University#6 · 35,977 sh | 35,977 | $138.5K | 0.03% | 0.0% |
| 7 | PFIZER#7 · 31,305 sh | 31,305 | $133.8K | 0.08% | 0.0% |
| 8 | Lynx1 Capital Management#8 · 30,800 sh | 30,800 | $118.6K | 0.02% | 0.0% |
| 9 | NANO CAP NEW MILLENNIUM GROWTH FUND L P#9 · 27,500 sh | 27,500 | $105.9K | 0.08% | 0.0% |
| 10 | GEODE CAPITAL MANAGEMENT#10 · 19,119 sh | 19,119 | $73.6K | 0.00% | -33.6% |
| 11 | Shay Capital#11 · 15,438 sh | 15,438 | $59.4K | <0.01% | +3.6% |
| 12 | BlackRock#12 · 9,711 sh | 9,711 | $37.4K | 0.00% | 0.0% |
| 13 | VANGUARD CAPITAL MANAGEMENT#13 · 7,060 sh | 7,060 | $27.2K | 0.00% | 0.0% |
| 14 | Nan Fung Group Ltd#14 · 5,000 sh | 5,000 | $19.3K | 0.01% | -82.9% |
| 15 | MORGAN STANLEY#15 · 3,145 sh | 3,145 | $12.1K | 0.00% | -1.4% |
| 16 | VANGUARD FIDUCIARY#16 · 3,095 sh | 3,095 | $11.9K | 0.00% | 0.0% |
| 17 | NewEdge Advisors#17 · 2,530 sh | 2,530 | $9.7K | 0.00% | New |
| 18 | Tower Research Capital (TRC)#18 · 1,710 sh | 1,710 | $6.6K | <0.01% | +56.5% |
| 19 | UBS Group AG#19 · 255 sh | 255 | $982.00 | 0.00% | -67.6% |
| 20 | SBI Securities , Ltd.#20 · 130 sh | 130 | $501.00 | — | +1200.0% |
| 21 | JPMORGAN CHASE#21 · 42 sh | 42 | $165.00 | 0.00% | 0.0% |
| 22 | CITIGROUP#22 · 41 sh | 41 | $158.00 | 0.00% | New |
| 23 | BARCLAYS PLC#23 · 6 sh | 6 | $23.00 | 0.00% | 0.0% |
Funds that sold out of BOLT in Q2 2026 (3)
Held BOLT at the end of Q1 2026 and filed a Q2 2026 13F without it. Not in the list above, because they no longer hold it. Largest prior position first.
| Institution | Shares sold | Value in Q1 2026 |
|---|---|---|
| Pivotal bioVenture Partners Investment Advisor42,581 sh | 42,581 | $172.0K |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP11,657 sh | 11,657 | $47.1K |
| Vanguard Global Advisers24 sh | 24 | $97.00 |
Source: Form 13F-HR filings on SEC EDGAR, Q2 2026. Values are as reported by each manager at quarter end. “% of portfolio” is the position’s share of the manager’s total reported 13F value for the same quarter. “New” means the manager filed a 13F for Q1 2026 without this position; a dash means no comparison is available. Where a manager’s own filing is internally inconsistent its value is withheld and it is listed last. 13F data shows reported holdings, not recommendations.